Skillman, New Jersey-based Kenvue Inc. (KVUE) operates as a consumer health company worldwide. Valued at $42.1 billion by market cap, the company offers a consumer health portfolio in self-care, skin health & beauty, and essential health products. The world’s largest pure-play consumer health company is expected to announce its fiscal third-quarter earnings for 2024 on Thursday, Oct. 24.
Ahead of the event, analysts expect KVUE to report a profit of $0.28 per share on a diluted basis, down 9.7% from $0.31 per share in the year-ago quarter. The company beat the consensus estimate in each of the last four quarters.
For the full year, analysts expect KVUE to report EPS of $1.08, down 16.3% from $1.29 in fiscal 2023. However, its EPS is expected to rise 13.9% year over year to $1.23 in fiscal 2025.
KVUE stock has underperformed the S&P 500’s ($SPX) 33.5% gains over the past 52 weeks, with shares up 8.9% during this period. Similarly, it underperformed the Consumer Staples Select Sector SPDR Fund’s (XLP) 21.6% gains over the same time frame.
On Aug. 6, KVUE shares closed up more than 14% after reporting its Q2 results. Its adjusted EPS of $0.32 surpassed Wall Street expectations of $0.28. The company’s revenue was $4 billion, topping Wall Street forecasts of $3.9 billion. KVUE expects full-year adjusted EPS to be between $1.10 and $1.20.
Analysts’ consensus opinion on KVUE stock is reasonably bullish, with a “Moderate Buy” rating overall. Out of 15 analysts covering the stock, six advise a “Strong Buy” rating, eight give a “Hold” rating, and one recommends a “Strong Sell.” KVUE’s average analyst price target is $23.31, indicating a potential upside of 6.7% from the current levels.
On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
